7 episodes

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

The Journal of Clinical Psychopharmacology Podcast The Journal of Clinical Psychopharmacology

    • Health & Fitness
    • 4.0 • 1 Rating

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

    Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior

    Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior

    Individuals with major depressive disorder and suicidal ideation are particularly vulnerable and may not respond as well to standard treatment as patients without suicidal ideation. In this author podcast, Dr. Dong-Jing Fu and Dr. Carla Canuso discuss the results of a pooled analysis of data from the ASPIRE studies, randomized placebo-controlled trials of esketamine, plus comprehensive standard-of-care treatment. The results, published in the September-October 2021 issue of the Journal of Clinical Psychopharmacology, suggest that esketamine can provide rapid relief of depressive symptoms in patients with MDD and acute suicidal ideation or behavior, especially in those with a history of prior suicide attempt.

    • 6 min
    The Placenta and Psychiatry?

    The Placenta and Psychiatry?

    Dr. Julia Ann Koretski reflects on the critical role of the placenta in drug metabolism and potential near- and long-term effects on postanatal life. The placenta was once viewed as a passive, almost mechanical barrier, but we are continuing to learn of the important ways it influences drug metabolism and development of conditions such as postnatal adaptation syndrome and schizophrenia. Dr. Koretski’s commentary is inspired by a Guest Editorial in the journal authored by Dr. Richard Shader, Founding Editor-in-Chief Emeritus of the Journal of Clinical Psychopharmacology. Dr. Koretski is Digital Editor of the journal.

    • 6 min
    Time to reconsider monoamine oxidase inhibitors (MAOIs) for Obsessive Compulsive Disorder? A case series using phenelzine

    Time to reconsider monoamine oxidase inhibitors (MAOIs) for Obsessive Compulsive Disorder? A case series using phenelzine

    Obsessive compulsive disorder (OCD) can often be effectively treated with cognitive behavioral therapy or serotonin reuptake inhibitors. About one-third of patients, however, do not receive adequate symptom relief. Jon E. Grant discusses the potential of monoamine oxidase inhibitors (MAOIs) in treatment-resistant OCD. In an article in the journal, Dr. Grant and his coauthors present new data from a case series of nine patients; three had marked improvement on phenelzine and three had some improvement. Large-scale trials are needed to fully assess the benefits and risks of the therapy in this population group.

    • 6 min
    Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness

    Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness

    Mass shootings have become a common occurrence in the United States and elsewhere. In this podcast, author Ira D. Glick discusses the research he and his colleagues conducted to analyze whether certain mass shooters had psychiatric illnesses and had received appropriate medication before they committed the violence. While the authors acknowledge the limitations in their research, their data suggest that many persons who commit domestic mass murders may have experienced compromising and untreated psychiatric illnesses.

    • 7 min
    Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?

    Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?

    Psychotic depression is a severely disabling illness and is more common than is generally realized. Unfortunately, there is no FDA-approved medication for its treatment. In this podcast, the Editor-in-Chief of the Journal of Clinical Psychopharmacology, Anthony J. Rothschild, discusses his opinions as to how this came about and encourages further research and development of a suitable medication with an eye toward FDA approval.

    • 12 min
    Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers

    Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers

    Authors Nicholas A. Mischel and Richard Balon discuss their commentary, “Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers.” Their commentary asks: How does this treatment fit into the broader repertoire in treating resistant depression and suicidal ideation or behavior, with both concepts ill-defined?

    • 8 min

Customer Reviews

4.0 out of 5
1 Rating

1 Rating

Top Podcasts In Health & Fitness

Listeners Also Subscribed To